


PHARMACEUTICAL 2019



PUMA BIOTECHNOLOGY INC. Rank 270 of 363





PHARMACEUTICAL 2019



PUMA BIOTECHNOLOGY INC. Rank 270 of 363

The relative strengths and weaknesses of PUMA BIOTECHNOLOGY INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PUMA BIOTECHNOLOGY INC. compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 71% points. The greatest weakness of PUMA BIOTECHNOLOGY INC. is the variable Other Liabilities, reducing the Economic Capital Ratio by 100% points.

The company's Economic Capital Ratio, given in the ranking table, is -23%, being 59% points below the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	203,003
Cost of Goods Sold	34,621
Intangible Assets	0
Liabilities, Current	67,115
Liabilities, Non-Current	0
Other Assets	52,156
Other Compr. Net Income	-12
Other Expenses	0
Other Liabilities	157,701
Other Net Income	-18,903
Other Revenues	250,991
Property and Equipment	3,963
Research and Development	164,854
Selling, General and Administrative Expense	146,188

Output Variable	Value in 1000 USD
Assets	259,122
Liabilities	224,816
Expenses	345,663
Revenues	250,991
Stockholders Equity	34,306
Net Income	-113,575
Comprehensive Net Income	-113,581
Economic Capital Ratio	-23%

